Virtual Library

Start Your Search

Amy Sullivan



Author of

  • +

    FP07 - Pathology (ID 109)

    • Event: WCLC 2020
    • Type: Posters (Featured)
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      FP07.16 - Trends in Biomarker Testing Among Advanced NSCLC Patients in Oncology Practice Settings in the US (ID 3325)

      00:00 - 00:00  |  Author(s): Amy Sullivan

      • Abstract
      • Slides

      Introduction

      The NCCN guidelines for non-small cell lung cancer (NSCLC) state that testing for gene alterations is important to identify patients where targeted therapies may be efficacious, and to avoid therapies that are unlikely to provide clinical benefit. With the availability of genomic biomarker therapies that have shown prolonged median overall survival, there is a need to ensure that patients with NSCLC who may receive targeted biomarker therapies are identified.

      The objective of this study is to understand ALK, BRAF, EGFR, and ROS1 genomic biomarker testing and treatment initiation trends among individuals diagnosed with advanced stages of NSCLC in real-world oncology practice settings.

      Methods

      This retrospective analysis of data from the ConcertAI Patient 360 electronic health record database focused on adult patients diagnosed with advanced (stage IIIb-IV) NSCLC (aNSCLC) from January 2013 – December 2019. Study metrics included the proportion of patients with any biomarker test and specific biomarker tests stratified by year of aNSCLC diagnosis, the time between aNSCLC diagnosis and first biomarker test result, and the time between first biomarker test result to initiation of treatment. The time between aNSCLC diagnosis and biomarker testing were reported as continuous and categorical variables. The time between biomarker testing to initiation of treatment are reported among patients who received their first biomarker test before starting their first line treatment and were tested 30 days prior or 360 days post aNSCLC diagnosis date.

      Table 1: Biomarker testing trends overtime by year of aNSCLC diagnosis

      table 1.png

      Results

      Among 6,876 aNSCLC patients diagnosed from 2013-2019, 3,301 had first line (1L) treatment of which 54.26% were tested for at least one of ALK, BRAF, EGFR, or ROS. Annual trends are presented in Table 1: Biomarker testing trends overtime by year of aNSCLC diagnosis. EGFR testing data were most prevalent overall (49.56%) followed by ALK (40.84%), ROS (27.51%), then BRAF (13.97%). Testing rates increased for all biomarkers over time, with the largest increase observed in BRAF testing. About half of patients were tested within 30 days of aNSCLC diagnosis. Median days from test to treatment were between 15-16 days for ALK, BRAF, EGFR, and ROS1.

      Conclusion

      This snapshot of biomarker testing shows that progress has been made in the proportion of patients tested, however biomarker testing rates in US oncology practices are still suboptimal. Additional research is needed on the reasons or barriers to ordering timely biomarker testing among advanced and metastatic stage NSCLC patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.